Kurapa kweCAR-T kweKenza yeMudumbu

Claudin18.2 (CLDN18.2) iprotein inobatana nemasero emudumbu inonzi tight junction isoform, inonyatsoonekwa mudumbu uye inobuda zvakanyanya pamusoro pemasero ekenza yemudumbu. CT041 (development code CG4006) chigadzirwa cheCAR-T chinogadzirwa neCLDN18.2. Ruzivo rwechikamu chekutanga runoratidza kuti chirwere ichi chinodzivirira bundu muvarwere vane kenza yemudumbu vane CLDN18.2 vasati varapwa zvakanyanya.

Kuwanda kweHER2 kunoonekwawo mune boka revanhu vane kenza yemudumbu. Mishonga yeCAR-T inotarirwa neHER2 yakaratidza kugona kwayo kurwisa bundu muzvidzidzo zvepamberi pekiriniki uye zvekutanga. TAC01-HER2 yeTriumvira Immunologics iri mumiedzo yekiriniki yePhase II.

• Kutarisa Kwakanyatsojeka: Nekutungamira masero eCAR-T kurwisa CLDN18.2 kana HER2, masero egomarara remudumbu anogona kuzivikanwa nekubviswa nemazvo, zvichideredza migumisiro isina bundu.

• Kukunda Kuramba Kurapwa Kwemitsetse Yakawanda: Mumiedzo yeCT041, boka revanhu vane kenza yemudumbu rakawana mukana wemhinduro chaiyo (ORR) we57.1%, mukana wekutonga chirwere (DCR) we75.0%, uye mukana wekurarama kwemwedzi mitanhatu (OS) we81.2% muvarwere vakanga vakundikana kurapwa kakawanda.

• Mhinduro Dzinogara Nguva DzoseKurapwa kweCLDN18.2-CAR-T kwakaita kuti mhinduro yemurwere isvike 44.8% kwemwedzi mitanhatu, zvichiratidza mukana wekubatsira kwenguva refu.

• Kurapa Kwakasiyana Nevamwe: Kushandisa masero eT emurwere kunoderedza njodzi yekurambwa uye kunowedzera kuchengetedzeka uye kushanda zvakanaka.

• Kuunganidzwa kwemasero eropa T ekunze
  Masero eT anobviswa muropa remurwere kuburikidza ne leukapheresis.

• Uinjiniya hweMajini
  Murabhoritari inoenderana neGMP, masero eT anogadzirwa kuti aratidze CAR inotarisa CLDN18.2 kana HER2, yobva yawedzerwa ex vivo.

• Kugadzirisa Kupera KwemaLymphoma
  Kugadzirira kwemishonga ye cyclophosphamide ne fludarabine kunopihwa kuti kuparadze ma lymphocytes endogenous uye kugadzira nzvimbo yakanaka yekuwedzera kwemasero eCAR-T.

• Kupinzwa kweCAR-T Cell
  Masero eCAR-T akagadzirwa anodzorerwa mumurwere netsinga.

• Kutarisa uye Kutarisira
  Mushure mekuisirwa mushonga, varwere vanoongororwa zvakanyanya kuti vaone kana paine cytokine release syndrome (CRS) uye kuti vane chepfu muuropi, uye vanobatsirwa nenguva yakakodzera.

• Ongororo Yenguva Pfupi yeCT041 (CLDN18.2-CAR-T)
  Pakati pevarwere makumi matatu nevanomwe vakarapwa kare, boka diki regomarara remudumbu rakawana ORR 57.1%, DCR 75.0%; 94.6% vakangowana CRS yeGiredhi 1-2 chete, vasina CRS yeGiredhi 3 kana kupfuura kana kuti neurotoxicity; Nguva yemhinduro yemwedzi mitanhatu yaive 44.8%.

• Satri-cel (yakanangawo kuCLDN18.2) Mhedzisiro Yekupedzisira yeChikamu Chekutanga
  Muvarwere 98 vane CLDN18.2-positive gastrointestinal cancer, ORR yaive 38.8%, DCR 91.8%; avhareji yekurarama pasina progression (mPFS) yaive mwedzi 4.4 (95% CI 3.7–6.6), avhareji yekurarama kwese (mOS) yaive mwedzi 8.8 (95% CI 7.1–10.2); 96.9% vakangosangana neGiredhi 1–2 CRS chete, vasina Giredhi 3+ CRS kana kufa kwakabatana nako.

• Ruzivo rwekutanga rweHER2-CAR-T
  Chidzidzo chekutanga chePhase I chakaratidza kuchengetedzeka kunogoneka; kuyedzwa kwekunyoresa kwePhase II kuri kuenderera mberi.

• Puratifomu Yetekinoroji Inotungamira
  BIOOCUS ine nzvimbo yekugadzira masero emhando yeGMP pasi rose, ichivimbisa kugadzirwa kwemasero eCAR-T kunoshanda uye kwakarongeka.

• Chikwata cheNyanzvi dzeMatunhu Akasiyana-siyana
  Chikwata chedu chinosanganisira nyanzvi dzine ruzivo rwakakura mukurapa zvirwere, oncology, uye masero, vachipa rubatsiro rwakakwana rwevanhu.

• Ruzivo Rwezvekurapa Rwepasi Pose
  Takarapa varwere vanobva kumativi ese epasi, tichiunganidza ruzivo rwakakura rwekuchengetedza uye kushanda zvakanaka kwemishonga iyi.

• Basa Rakakwana Rekusvika Kumagumo
  Kubva pakugadzira nzira dzekurapa uye kubatanidza kurapwa kwekunze kwenyika kusvika pakuteverwa kwenguva refu mushure mekunwa mushonga, BIOOCUS inopa rutsigiro rwenguva imwe chete.